-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient's body, announced today that it will take part in two fireside chats, the first at the Piper Sandler 34th Annual Healthcare Conference, to be held November 29-December 1 in New York, and the second at the JMP Securities Hematology & Oncology Summit, to be held virtually December 6-7.
During the fireside chats Cue Biopharma will provide an updated corporate overview highlighting recent data from its lead clinical program, CUE-101, representative of the IL-2-based CUE-100 series, currently being evaluated in a Phase 1 trial as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) for the treatment of patients with HPV+ recurrent/metastatic head and neck cancer. The discussion will also include the Company's second clinical asset from the CUE-100 series, CUE-102, currently being evaluated in a Phase 1 trial for the treatment of Wilms' Tumor 1 (WT1) positive cancers, as well as other pipeline and platform developments.
Presentation Details:
Piper Sandler 34th Annual Healthcare Conference
Date and Time: Wednesday, November 30 at 10:00-10:25 a.m. ET
Webcast Link:
Presenter: Daniel Passeri, chief executive officer, Cue Biopharma
JMP Securities Hematology & Oncology Summit
Date and Time: Tuesday, December 6 at 12:40-1:00 p.m. ET
Webcast Link:
Presenter: Daniel Passeri, chief executive officer, Cue Biopharma
Live and archived webcasts of the fireside chats will be available on the Events page in the Investors and Media section of the Company's website at . The webcasts will be archived for 30 days.
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient's body to transform the treatment of cancer. The company's proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) and biologics are designed to harness the body's intrinsic immune system as T cell engagers without the need for ex vivo manipulation.
Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
For more information please visit and follow us on Twitter at
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
Media Contact
Maya Romanchuk
LifeSci Communications
mromanchuk@lifescicomms.com
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient's body, announced today that it will take part in two fireside chats, the first at the Piper Sandler 34th Annual Healthcare Conference, to be held November 29-December 1 in New York, and the second at the JMP Securities Hematology & Oncology Summit, to be held virtually December 6-7.
波士顿,2022年11月22日(环球社)--临床阶段生物制药公司Cue Biophma,Inc.(纳斯达克股票代码:CUE)今天宣布,它将参加两次炉边聊天,第一次是11月29-12月1日在纽约举行的Piper Sandler第34届年度医疗会议,第二次是12月6-7日举行的JMP证券血液学和肿瘤学峰会。
During the fireside chats Cue Biopharma will provide an updated corporate overview highlighting recent data from its lead clinical program, CUE-101, representative of the IL-2-based CUE-100 series, currently being evaluated in a Phase 1 trial as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) for the treatment of patients with HPV+ recurrent/metastatic head and neck cancer. The discussion will also include the Company's second clinical asset from the CUE-100 series, CUE-102, currently being evaluated in a Phase 1 trial for the treatment of Wilms' Tumor 1 (WT1) positive cancers, as well as other pipeline and platform developments.
Presentation Details:
在炉边聊天中,Cue Biophma将提供最新的公司概况,重点介绍其主要临床计划CUE-101的最新数据。CUE-101是基于IL-2的CUE-100系列的代表,目前正在作为单一疗法和与凯特鲁达®(培布罗利珠单抗)联合治疗人乳头瘤病毒阳性复发/转移性头颈癌患者的第一阶段试验进行评估。讨论还将包括该公司来自CUE-100系列的第二项临床资产CUE-102,目前正在对治疗Wilms肿瘤1(WT1)阳性癌症的第一阶段试验进行评估,以及其他管道和平台开发。
演示文稿详情:
Piper Sandler 34th Annual Healthcare Conference
Date and Time: Wednesday, November 30 at 10:00-10:25 a.m. ET
Webcast Link:
Presenter: Daniel Passeri, chief executive officer, Cue Biopharma
派珀·桑德勒第34届年度医疗会议
日期和时间:11月30日(星期三)上午10:00-10:25外星人
网络直播链接:
主讲人:Daniel·帕塞里,Cue Biophma首席执行官
JMP Securities Hematology & Oncology Summit
Date and Time: Tuesday, December 6 at 12:40-1:00 p.m. ET
Webcast Link:
Presenter: Daniel Passeri, chief executive officer, Cue Biopharma
JMP证券血液与肿瘤学峰会
日期和时间:12月6日(星期二)中午12:40-1:00外星人
网络直播链接:
主讲人:Daniel·帕塞里,Cue Biophma首席执行官
Live and archived webcasts of the fireside chats will be available on the Events page in the Investors and Media section of the Company's website at . The webcasts will be archived for 30 days.
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient's body to transform the treatment of cancer. The company's proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) and biologics are designed to harness the body's intrinsic immune system as T cell engagers without the need for ex vivo manipulation.
Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
For more information please visit and follow us on Twitter at
炉边聊天的现场和存档网络直播将在公司网站投资者和媒体部分的活动页面上提供,网址为:。网络直播将存档30天。
关于Cue Biophma
CUE Biophma是一家临床阶段的生物制药公司,该公司正在开发一种新型的可注射生物制剂,直接在患者体内选择性地结合和调节肿瘤特异性T细胞,以改变癌症的治疗。该公司的专有平台,免疫统计™(T细胞的选择性靶向和改变)生物制品的设计是为了利用人体的内在免疫系统作为T细胞的结合者,而不需要体外操作。
我们总部设在马萨诸塞州波士顿,由经验丰富的管理团队和独立董事会领导,在免疫学和免疫肿瘤学以及蛋白质生物制剂的设计和临床开发方面拥有深厚的专业知识。
有关更多信息,请访问并在Twitter上关注我们,地址为
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
投资者联系方式
玛丽·坎皮内尔
企业传播部高级董事
Cue Biophma,Inc.
邮箱:mcampinell@cueBio.com
Media Contact
Maya Romanchuk
LifeSci Communications
mromanchuk@lifescicomms.com
媒体联系人
玛雅·罗曼丘克
生活科学传播
邮箱:mRomchuk@lifescicomms.com
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧